WO2002094200A3 - Pulmonary administration of chemically modified insulin - Google Patents

Pulmonary administration of chemically modified insulin Download PDF

Info

Publication number
WO2002094200A3
WO2002094200A3 PCT/US2002/016464 US0216464W WO02094200A3 WO 2002094200 A3 WO2002094200 A3 WO 2002094200A3 US 0216464 W US0216464 W US 0216464W WO 02094200 A3 WO02094200 A3 WO 02094200A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemically modified
pulmonary administration
insulin
modified insulin
derivatives
Prior art date
Application number
PCT/US2002/016464
Other languages
French (fr)
Other versions
WO2002094200A2 (en
Inventor
John S Patton
Mei-Chang Kuo
J Milton Harris
Chester Leach
Kimberly Perkins
Blaine Bueche
Original Assignee
Inhale Therapeutic Syst
Shearwater Corp
John S Patton
Mei-Chang Kuo
J Milton Harris
Chester Leach
Kimberly Perkins
Blaine Bueche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002590921A priority Critical patent/JP2004535401A/en
Priority to EA200301222A priority patent/EA007408B1/en
Application filed by Inhale Therapeutic Syst, Shearwater Corp, John S Patton, Mei-Chang Kuo, J Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche filed Critical Inhale Therapeutic Syst
Priority to APAP/P/2003/002918A priority patent/AP1763A/en
Priority to AU2002303869A priority patent/AU2002303869B2/en
Priority to KR10-2003-7014954A priority patent/KR20030097876A/en
Priority to NZ529572A priority patent/NZ529572A/en
Priority to CA002447236A priority patent/CA2447236A1/en
Priority to HU0400442A priority patent/HUP0400442A2/en
Priority to BR0209896-2A priority patent/BR0209896A/en
Priority to EP02731931A priority patent/EP1395294A4/en
Priority to IL15886202A priority patent/IL158862A0/en
Priority to SK1553-2003A priority patent/SK15532003A3/en
Priority to MXPA03010649A priority patent/MXPA03010649A/en
Publication of WO2002094200A2 publication Critical patent/WO2002094200A2/en
Publication of WO2002094200A3 publication Critical patent/WO2002094200A3/en
Priority to IL158862A priority patent/IL158862A/en
Priority to IS7043A priority patent/IS7043A/en
Priority to NO20035157A priority patent/NO20035157D0/en
Priority to HR20030949A priority patent/HRP20030949A2/en
Priority to BG108494A priority patent/BG108494A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
PCT/US2002/016464 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin WO2002094200A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IL15886202A IL158862A0 (en) 2001-05-21 2002-05-21 An insulin composition for pulmonary administration
EP02731931A EP1395294A4 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
SK1553-2003A SK15532003A3 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
EA200301222A EA007408B1 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
KR10-2003-7014954A KR20030097876A (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
NZ529572A NZ529572A (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
CA002447236A CA2447236A1 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
HU0400442A HUP0400442A2 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin and process for its preparation
BR0209896-2A BR0209896A (en) 2001-05-21 2002-05-21 Insulin composition for pulmonary administration, and methods for supplying insulin to a mammalian subject, to provide a non-immunogenic insulin composition and a long-acting insulin composition for administration to an individual's lung.
JP2002590921A JP2004535401A (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
AU2002303869A AU2002303869B2 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
APAP/P/2003/002918A AP1763A (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin
MXPA03010649A MXPA03010649A (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin.
IL158862A IL158862A (en) 2001-05-21 2003-11-13 Insulin composition for pulmonary administration
IS7043A IS7043A (en) 2001-05-21 2003-11-19 Administration of chemically transformed insulin into the lungs
NO20035157A NO20035157D0 (en) 2001-05-21 2003-11-20 Pulmonary administration of chemically modified insulin
HR20030949A HRP20030949A2 (en) 2001-05-21 2003-11-21 Pulmonary administration of chemically modified insulin
BG108494A BG108494A (en) 2001-05-21 2003-12-22 Pulmonary administration of chemically modified insulin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29242301P 2001-05-21 2001-05-21
US60/292,423 2001-05-21

Publications (2)

Publication Number Publication Date
WO2002094200A2 WO2002094200A2 (en) 2002-11-28
WO2002094200A3 true WO2002094200A3 (en) 2003-02-20

Family

ID=23124608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016464 WO2002094200A2 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin

Country Status (35)

Country Link
US (3) US6838076B2 (en)
EP (1) EP1395294A4 (en)
JP (1) JP2004535401A (en)
KR (1) KR20030097876A (en)
CN (2) CN1314445C (en)
AP (1) AP1763A (en)
AR (1) AR033903A1 (en)
AU (1) AU2002303869B2 (en)
BG (1) BG108494A (en)
BR (1) BR0209896A (en)
CA (1) CA2447236A1 (en)
CO (1) CO5540371A2 (en)
CZ (1) CZ20033182A3 (en)
EA (1) EA007408B1 (en)
EC (1) ECSP034855A (en)
GE (1) GEP20063917B (en)
HR (1) HRP20030949A2 (en)
HU (1) HUP0400442A2 (en)
IL (2) IL158862A0 (en)
IS (1) IS7043A (en)
LT (1) LT5153B (en)
LV (1) LV13197B (en)
MA (1) MA26185A1 (en)
MX (1) MXPA03010649A (en)
MY (1) MY137181A (en)
NO (1) NO20035157D0 (en)
NZ (1) NZ529572A (en)
OA (1) OA13136A (en)
PL (1) PL366911A1 (en)
SK (1) SK15532003A3 (en)
TN (1) TNSN03116A1 (en)
TR (1) TR200400295T2 (en)
WO (1) WO2002094200A2 (en)
YU (1) YU98503A (en)
ZA (1) ZA200309085B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266964B2 (en) 2011-01-06 2016-02-23 Dyax Corp. Method of treating hereditary angioedema using plasma kallikrein binding antibodies

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP2004535401A (en) * 2001-05-21 2004-11-25 ネクター セラピューティックス Pulmonary administration of chemically modified insulin
EP1270012A1 (en) * 2001-06-21 2003-01-02 Pfizer Products Inc. Use of pulmonary administration of insulin for treatment of diabetes
AU2002367032B8 (en) * 2001-12-21 2008-10-23 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2338523B1 (en) 2003-02-26 2024-01-17 Nektar Therapeutics Polymer-factor viii moiety conjugates
CA2521381C (en) * 2003-04-11 2020-05-26 Kenneth Hinds Method for preparation of site-specific protein conjugates
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
CA2537113A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
GB0328629D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
UA91512C2 (en) 2004-07-19 2010-08-10 Биокон Лимитед Insulin-oligomer conjugates, formulations and uses thereof
DK1786784T3 (en) 2004-08-20 2011-02-14 Mannkind Corp Catalysis of diketopiperazine synthesis
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
US20060046852A1 (en) * 2004-08-26 2006-03-02 Rowe Richard E Wide area gaming system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8245758B2 (en) * 2006-10-30 2012-08-21 GM Global Technology Operations LLC Coulomb damped disc brake rotor and method of manufacturing
WO2006076277A1 (en) * 2005-01-10 2006-07-20 Nektar Therapeutics Compositions and methods for increasing the bioavailability of pulmonarily administered insulin
US20090036353A1 (en) * 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2428510T3 (en) 2005-02-02 2013-11-08 Novo Nordisk A/S Insulin derivatives
WO2006082205A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
US20060271011A1 (en) * 2005-05-25 2006-11-30 Mock Bradley D Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20070124218A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
CA2634974A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for improved cardiac function
IN2015DN00888A (en) 2006-02-22 2015-07-10 Mannkind Corp
US20070292404A1 (en) * 2006-03-27 2007-12-20 Biosynexus Incorporated Antimicrobial polymer conjugates
EP2044097A4 (en) 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
DK1873166T3 (en) * 2006-06-30 2010-12-20 Conaris Res Inst Ag Improved sgp 130Fc dimers
EP2049151A4 (en) * 2006-07-17 2010-03-24 Quintessence Biosciences Inc Methods and compositions for the treatment of cancer
JP5550338B2 (en) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー/エス PEGylated insulin
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
WO2008067158A2 (en) 2006-11-13 2008-06-05 Auxagen, Inc. METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2008084051A1 (en) * 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
US7943141B2 (en) * 2007-02-28 2011-05-17 Serina Therapeutics, Inc. Activated polyoxazolines and compositions comprising the same
ES2563038T3 (en) 2007-04-30 2016-03-10 Novo Nordisk A/S Method for drying a protein composition, a dry protein composition and a pharmaceutical composition comprising the dry protein
WO2009020434A1 (en) * 2007-08-07 2009-02-12 Nanomaterials Technology Pte Ltd A process for making micro-sized protein particles
EP2192904B1 (en) * 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
KR101234540B1 (en) 2007-10-16 2013-02-19 바이오콘 리미티드 An orally administerable solid pharmaceutical composition and a process thereof
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
ES2618073T3 (en) 2008-03-14 2017-06-20 Novo Nordisk A/S Insulin analogs stabilized against proteases
HUE032287T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease stabilized, acylated insulin analogues
TWI451876B (en) * 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
US8488661B2 (en) * 2008-06-13 2013-07-16 Verizon Patent And Licensing Inc. Systems and methods for data streaming
KR101655053B1 (en) 2008-06-13 2016-09-07 맨카인드 코포레이션 A dry powder inhaler and system for drug delivery
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (en) 2008-06-20 2021-06-22 Mannkind Corp inhalation system
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
CN102159219B (en) * 2008-09-16 2015-06-24 圣路易斯大学 Method of enhancing tgf-beta signalling
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010039985A1 (en) 2008-10-01 2010-04-08 Quintessence Biosciences, Inc. Therapeutic Ribonucleases
DK2379511T3 (en) 2008-12-29 2015-01-12 Mannkind Corp Substituted diketopiperazinanaloger for use as pharmaceutical management funds
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP2013516389A (en) 2009-01-06 2013-05-13 ダイアックス コーポレーション Treatment of mucositis with kallikrein inhibitors
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (en) 2009-06-12 2018-07-06 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
MX2012001399A (en) 2009-07-31 2012-03-21 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate.
AU2010318637A1 (en) 2009-10-13 2012-05-31 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
JP2013526840A (en) 2009-12-21 2013-06-27 ファーマシーネ,インコーポレイテッド Recombinant butyrylcholinesterase and its truncated form
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (en) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP2014509603A (en) 2011-03-15 2014-04-21 ノヴォ ノルディスク アー/エス Human insulin analogues and human insulin derivatives containing cysteine substitutions
CN102675452B (en) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 Tool continues the conjugate of insulin human that is hypoglycemic and that combined by height and analogue
CA3078334C (en) 2011-04-01 2022-08-09 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
CN102504022A (en) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 Proinsulin containing protecting lysine and preparation method for insulin by utilizing proinsulin
CN104364260B (en) 2012-04-11 2017-02-22 诺和诺德股份有限公司 insulin formulations
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR102391750B1 (en) 2013-03-15 2022-04-28 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (en) 2013-07-18 2022-11-09 맨카인드 코포레이션 Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (en) 2013-08-05 2016-04-20 曼金德公司 Insufflation apparatus and methods
JP6822839B2 (en) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート Modified therapeutic agents and their compositions
PL3055325T3 (en) 2013-10-07 2018-06-29 Novo Nordisk A/S Novel derivative of an insulin analogue
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA41116A (en) 2014-12-01 2017-10-10 Ferring Bv SELECTIVE IL-6 TRANS-SIGNALING INHIBITOR COMPOSITIONS
EP3912636A1 (en) 2014-12-01 2021-11-24 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
CN116077648A (en) 2015-12-11 2023-05-09 武田药品工业株式会社 Plasma kallikrein inhibitors and their use for the treatment of hereditary angioedema attacks
CA3020567A1 (en) 2016-04-12 2017-10-19 Cell and Molecular Tissue Engineering, LLC Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site
BR112019007819B1 (en) * 2016-11-02 2022-06-14 Dow Global Technologies Llc SOLID NON-AQUEOUS GEL AIR ODORANT
CA3046583A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US6427681B1 (en) * 1993-01-29 2002-08-06 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4654324A (en) 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
DOP1982004086A (en) 1981-08-27 1988-03-22 Lilly Co Eli PHARMACEUTICAL FORMULA INCLUDING HUMAN INSULIN AND HUMAN PROINSULIN
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
ATE136315T1 (en) 1989-05-27 1996-04-15 Sumitomo Pharma METHOD FOR THE PRODUCTION OF POLYETHYLENE GLYCOL DERIVATIVES AND MODIFIED PROTEINS.
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP3051145B2 (en) * 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5889153A (en) * 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19628143A1 (en) 1996-07-12 1998-01-15 Basf Ag Process for the preparation of an aqueous polymer dispersion
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
ES2202899T3 (en) 1997-10-24 2004-04-01 Novo Nordisk A/S ADDED FROM HUMAN INSULIN DERIVATIVES.
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
AU745290B2 (en) 1998-07-27 2002-03-21 Emisphere Technologies, Inc. Pulmonary delivery of active agents
EP1137431A1 (en) * 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
EP1392350A2 (en) * 2001-05-11 2004-03-03 Aradigm Corporation Optimization of the molecular properties and formulation of proteins delivered by inhalation
JP2004535401A (en) * 2001-05-21 2004-11-25 ネクター セラピューティックス Pulmonary administration of chemically modified insulin
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DK1418890T3 (en) * 2001-08-16 2008-08-11 Baxter Int Propellant-based microparticle formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US6427681B1 (en) * 1993-01-29 2002-08-06 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266964B2 (en) 2011-01-06 2016-02-23 Dyax Corp. Method of treating hereditary angioedema using plasma kallikrein binding antibodies

Also Published As

Publication number Publication date
BR0209896A (en) 2004-08-17
AP2003002918A0 (en) 2003-12-31
IL158862A0 (en) 2004-05-12
KR20030097876A (en) 2003-12-31
LT5153B (en) 2004-08-25
CN1582171A (en) 2005-02-16
CN1314445C (en) 2007-05-09
AR033903A1 (en) 2004-01-07
MXPA03010649A (en) 2005-10-05
BG108494A (en) 2004-07-30
CZ20033182A3 (en) 2004-09-15
CO5540371A2 (en) 2005-07-29
US20030118510A1 (en) 2003-06-26
SK15532003A3 (en) 2004-06-08
CN101045166A (en) 2007-10-03
GEP20063917B (en) 2006-09-11
IS7043A (en) 2003-11-19
IL158862A (en) 2008-07-08
HRP20030949A2 (en) 2005-04-30
JP2004535401A (en) 2004-11-25
NO20035157D0 (en) 2003-11-20
OA13136A (en) 2006-12-13
YU98503A (en) 2006-05-25
NZ529572A (en) 2006-02-24
TNSN03116A1 (en) 2005-12-23
MY137181A (en) 2009-01-30
HUP0400442A2 (en) 2005-03-29
EA200301222A1 (en) 2004-08-26
ZA200309085B (en) 2004-11-22
AP1763A (en) 2007-08-02
TR200400295T2 (en) 2005-04-21
LT2003107A (en) 2004-05-25
US20030216542A1 (en) 2003-11-20
EA007408B1 (en) 2006-10-27
ECSP034855A (en) 2004-03-23
EP1395294A4 (en) 2006-01-11
PL366911A1 (en) 2005-02-07
MA26185A1 (en) 2004-07-01
WO2002094200A2 (en) 2002-11-28
AU2002303869B2 (en) 2007-08-16
LV13197B (en) 2004-10-20
EP1395294A2 (en) 2004-03-10
US20050152848A1 (en) 2005-07-14
US6838076B2 (en) 2005-01-04
CA2447236A1 (en) 2002-11-28
US6890518B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
WO2002094200A3 (en) Pulmonary administration of chemically modified insulin
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
MXPA03007591A (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues.
EP1329458A3 (en) Peptides that lower blood glucose levels
IL174154A (en) Glp-1 derivatives, pharmaceutical compositions comprising them and their use in manufacturing medicaments
ZA200402688B (en) Method and composition for preventing or reducing the symptons of insulin resistance syndrome.
WO2003011226A3 (en) Products and drug delivery vehicles
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
WO2004058837A3 (en) Ampholytic copolymer and use thereof
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2003051389A3 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
HUP0400666A2 (en) Inhalation capsules
IL174479A (en) Hemiasterlin derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2003090696A3 (en) Methods and products for mucosal delivery
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
AU2003267581A1 (en) Drug delivery
PL398391A1 (en) Hydroxyalkylstarch and polypeptide conjugate, process for the preparation of that conjugate, the use thereof and the pharmaceutical composition containing the hydroxyalkylstarch and polypeptide conjugate
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2005092362A3 (en) Pharmaceutical combined preparation containing a therapeutic protein
WO2004006830A3 (en) Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-985/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002303869

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447236

Country of ref document: CA

Ref document number: 158862

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 529572

Country of ref document: NZ

Ref document number: 1020037014954

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 347.03

Country of ref document: BZ

Ref document number: 2002590921

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501191

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1823/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2003-3182

Country of ref document: CZ

Ref document number: 2002731931

Country of ref document: EP

Ref document number: 2003/09085

Country of ref document: ZA

Ref document number: P20030949A

Country of ref document: HR

Ref document number: PA/a/2003/010649

Country of ref document: MX

Ref document number: 200320030131

Country of ref document: LV

Ref document number: 028103556

Country of ref document: CN

Ref document number: 200309085

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002918

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 1200301068

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200301222

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2003107

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: 15532003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 5398

Country of ref document: GE

Ref document number: 7227

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 10849402

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004/00295

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 2002731931

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2003107

Country of ref document: LT

WWG Wipo information: grant in national office

Ref document number: 2003107

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: PV2003-3182

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 347.03

Country of ref document: BZ

WWP Wipo information: published in national office

Ref document number: 347.03

Country of ref document: BZ

WWP Wipo information: published in national office

Ref document number: 529572

Country of ref document: NZ